ArticleCirculation. Cardiovascular interventions2023
Transcatheter Aortic Valve Replacement in Patients With Reduced Ejection Fraction and Nonsevere Aortic Stenosis.
Article in Circulation. Cardiovascular interventions, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04914481 (AnaTomic Stenosis Severity Derived From Computed Tomography as a Prognostic Marker in Patients With Low-flow Low-gradient Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation), which is not on this map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
AnaTomic Stenosis Severity Derived From Computed Tomography as a Prognostic Marker in Patients With Low-flow Low-gradient Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation
Who cites it
14 citing papers in PubMed, 38 citations in OpenAlex.
- Heart Failure and Moderate Aortic Stenosis: is Early TAVI the Better Strategy?European heart journal supplements : journal of the European Society of Cardiology · 2026Article
- Valvular Heart Disease and Its Association With Death in Advanced Heart Failure.Journal of the American Heart Association · 2025Article
- Early and Very Early Post-Transcatheter Aortic Valve Implantation Infective Endocarditis: Imaging Challenges.Reviews in cardiovascular medicine · 2025Review
- Clinical Outcomes of Transcatheter Aortic Valve Replacement in Patients with Various Flow-Gradient and Ejection Fraction Profiles.Anatolian journal of cardiology · 2025Article
- Prognostic and therapeutic implications of a low aortic valve calcium score in patients with low-gradient aortic stenosis.European heart journal. Cardiovascular Imaging · 2025Article
- Current Management and Therapy of Severe Aortic Stenosis and Future Perspective.Journal of atherosclerosis and thrombosis · 2024Review
- Moderate Aortic Stenosis-Advanced Imaging, Risk Assessment, and Treatment Strategies.Structural heart : the journal of the Heart Team · 2024Review
- Early Aortic Valve Replacement in Moderate Aortic Stenosis.JACC. Advances · 2024Article
- Sex Differences in Aortic Stenosis: From the Pathophysiology to the Intervention, Current Challenges, and Future Perspectives.Journal of clinical medicine · 2024Review
- TAVI in moderate aortic stenosis: the earlier the better?EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2024Article
- Survival outcomes of TAVR and self-expanding versus balloon-expandable valves in patients with advanced cardiac dysfunction.ESC heart failure · 2024Article
- Moderate aortic stenosis in the dysfunctional ventricle: should it be treated?European heart journal supplements : journal of the European Society of Cardiology · 2024Article
- Discordant Low-Gradient Aortic Stenosis: Assessing the Valve and the Myocardium.Texas Heart Institute journal · 2024Article
- Transcatheter aortic valve replacement: Past, present, and future.Clinical cardiology · 2024Review
Corrections and comments
- Commented on by
Authors and funding
21 authors at 10 institutions in 7 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe potential benefit of transcatheter aortic valve replacement (TAVR) in patients with nonsevere aortic stenosis (AS) and heart failure is controversial. This study aimed to assess outcomes of patients with nonsevere low-gradient AS (LGAS) and reduced left ventricular ejection fraction undergoing TAVR or medical management.
methodsPatients undergoing TAVR for LGAS and reduced left ventricular ejection fraction (<50%) were included in a multinational registry. True-severe low-gradient AS (TS-LGAS) and pseudo-severe low-gradient AS (PS-LGAS) were classified according to computed tomography-derived aortic valve calcification thresholds. A medical control group with reduced left ventricular ejection fraction and moderate AS or PS-LGAS was used (Medical-Mod). Adjusted outcomes between all groups were compared. Among patients with nonsevere AS (moderate or PS-LGAS), outcomes after TAVR and medical therapy were compared using propensity score-matching.
resultsA total of 706 LGAS patients undergoing TAVR (TS-LGAS, N=527; PS-LGAS, N=179) and 470 Medical-Mod patients were included. After adjustment, both TAVR groups showed superior survival compared with Medical-Mod patients (all
conclusionsAmong patients with nonsevere AS and reduced left ventricular ejection fraction, TAVR represents a major predictor of superior survival. These results reinforce the need for randomized-controlled trials comparing TAVR versus medical management in heart failure patients with nonsevere AS. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT04914481.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.